Background
==========

Osteoporosis (OP) is a systemic disease characterized by reduced bone strength and damaged bone microstructure, resulting in increased bone fragility and proneness to fracture \[[@b1-medscimonit-26-e920485]\]. According to the World Health Organization (WHO) statistics, 200 million people suffer from OP, and with the aging of the global population, this figure will continue to increase \[[@b2-medscimonit-26-e920485]\]. As a result of this phenomenon, the soaring expense of medical treatment and nursing has become an indisputable fact. It is predicted that in China, expenses due to OP-related fracture treatment will reach 25.43 billion dollars in 2050 \[[@b3-medscimonit-26-e920485]\]. At present, anti-osteoporosis drugs mainly include anti-catabolic agents, anabolic agents and supplements that utilize other mechanisms, such as calcium, vitamin K2 and strontium \[[@b4-medscimonit-26-e920485]\].

Because traditional Chinese medicine (TCM) can play a positive role in the treatment of OP \[[@b5-medscimonit-26-e920485]\], an increased number of researchers have begun to explore Chinese herbal medicines. *Cuscutae semen* (CS), which is derived from the dry and mature seeds of *Cuscuta australis* R. Br. or *Cuscuta chinensis* Lam., is a widely used Chinese medicine with a long history of use \[[@b6-medscimonit-26-e920485],[@b7-medscimonit-26-e920485]\]. Previous studies have shown that CS can nourish the kidneys and liver, prevent miscarriages and protect the eyesight \[[@b8-medscimonit-26-e920485]\]. Moreover, it also plays a certain role in the treatment of impotence and the seminal inhibition of the growth of tumor cells \[[@b9-medscimonit-26-e920485],[@b10-medscimonit-26-e920485]\]. In addition to these biological functions, Yao et al. showed that CS can promote the proliferation of bone marrow mesenchymal stem cells and osteoblasts and inhibit osteoclast activity in rat bone cells. Moreover, Yang et al. demonstrated that CS can induce osteogenic activity in human osteoblast-like MG-63 cells \[[@b11-medscimonit-26-e920485]\]. Although some ingredients of CS have been extracted and verified \[[@b12-medscimonit-26-e920485]--[@b14-medscimonit-26-e920485]\], the identities of numerous other components and how they relieve OP by influencing bone metabolism are still largely unknown.

Recently, the concept of network pharmacology has been proposed as a new method to predict the mechanisms of the effects of drug therapy on disease at the whole organismal level \[[@b15-medscimonit-26-e920485]\]. With the aid of molecular biology and related database information, network pharmacology has shifted from the traditional "one drug, one target" strategy to the "drug-target-pathway-disease" strategy to provide a more comprehensive understanding of TCM mechanisms \[[@b16-medscimonit-26-e920485]\]. Therefore, this study adopted a network pharmacology approach to analyze and construct an "ingredient-target-pathway" network of the effects of CS on the treatment of OP. The multitarget and multiple pathway network of CS was also revealed from a holistic point of view, providing a reference for further exploring the mechanism underlying its treatment effects on OP.

Material and Methods
====================

Acquisition of chemical ingredients and screening of active ingredients
-----------------------------------------------------------------------

"*Cuscutae semen"* was used as the key word to search for all the chemical information about CS in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (*<http://lsp.nwsuaf.edu.cn/tcmsp.php>*) \[[@b17-medscimonit-26-e920485]\] and in the literature review. By referring to multiple standards in the literature, an oral availability (OB) greater than 30% and a pharmacokinetic value (DL) greater than 0.18 were used as the limiting conditions to screen the active ingredients in the database \[[@b18-medscimonit-26-e920485]\]. As a result, 11 chemical ingredients were identified, and PubChem (*<http://pubchem.ncbi.nlm.nih.gov/>*) was used to retrieve the active ingredients and obtain their 3D structures in mol2 format for further analysis.

Target prediction of the active ingredients
-------------------------------------------

The targets of the active ingredients in CS were queried by using the TCMSP target module, and the target protein name was transformed into a gene name by using Perl (*<http://www.perl.org/>*) and the UniProt database (*<http://www.UniProt.org/>*).

Target prediction of disease
----------------------------

To reveal the genes possibly related to disease, "osteoporosis" was used as the keyword, and the GeneCards database (*<https://www.genecards.org/>*), PubMed website (*<https://www.ncbi.nlm.nih.gov>*) and CTD database (*<https://ctdbase.org/tools/batchQuery.go>*) were utilized. All of these online tools are continuously updated with information about human genes and genetic diseases, providing a relatively comprehensive overview of research results. We removed duplicate targets from the search results.

Intersection of active ingredients and disease targets
------------------------------------------------------

We first downloaded the R package (*<https://www.rproject.org/>*) and entered the command code to install the toolkit for drawing a Venn diagram in R. Then, by using the previously prepared files that contained the active ingredients of CS and the disease targets, a specific command code was entered in R, which generated the Venn diagram and a list describing the specific outcomes of the analysis. This "ingredients to disease" list was used in the following steps.

Network construction and analysis
---------------------------------

The "ingredients to disease" list was imported into Cytoscape 3.6.1 software (*<https://cytoscape.org/>*); then, the CS ingredient names and OP names were also introduced into Cytoscape to construct the model of the medicine-ingredients-disease-targets (M-I-D-T) network. In the network construction, nodes were used to represent molecules or target proteins, and edges were used to represent the relationships among ingredients, disease and targets.

Construction of the protein interaction network
-----------------------------------------------

The "ingredients to disease" list was imported into the Search Tool for the Retrieval of Interacting Genes (STRING) database (*<http://string-db.org>*), which is a protein--protein interaction (PPI) database that can search for known proteins and predict PPIs \[[@b19-medscimonit-26-e920485]\]. In the operating interface, we limited the species to "Homo sapiens" and set the minimum interaction threshold to 0.7 to determine the relationships between potential targets of CS in the treatment of OP. Next, we utilized the R package to screen the hub proteins. The basic principle was to determine the number of junction nodes between all proteins and the top 30 proteins.

Gene ontology and pathway enrichment analysis
---------------------------------------------

Bioconductor (*<http://www.bioconductor.org/>*) provides tools for the analysis and interpretation of high-throughput genomic data. It uses the programming software R, which is an open source and open development software \[[@b20-medscimonit-26-e920485]\]. With the help of the R package, we successfully installed this useful analysis tool and then ran the code. The enrichment analysis of Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were carried out on the genes in the ingredient-OP target network, and the results were obtained (*P*-adjusted value \<0.01). By using the count score, we selected the top 20 for presentation.

Molecular docking
-----------------

Five targets with a maximum count score in the target interaction network obtained from the PPI analysis were selected. They were mitogen-activated protein kinase 8 (MAPK8), epidermal growth factor receptor (EGFR), cyclin D1 (CCND1), interleukin-6 (IL-6), and vascular endothelial growth factor A (VEGFA). All of these were searched in the PDB database (*<http://www.rcsb.org/pdb/home/home.do>*), which is the most important database containing atomic-level 3D structural data for biological macromolecules (proteins, nucleic acids and sugars) \[[@b21-medscimonit-26-e920485]\], and the conformations were screened according to the following conditions: 1) protein structure was obtained by an x-ray diffraction method; 2) protein structure had a resolution less than 3 Å; 3) protein was typed; and 4) protein structures reported in previous docking studies were preferred. Then, Autotools was used to remove the excess protein chains and ligands, and hydrogenation was performed to remove the water molecules. AutoGrid was used to calculate the energy lattice, to set the grid box coordinates, and to set the distance of each small grid point to 0.1 nm. Finally, Autodock Vina 4.2 (*<http://vina.scripps.edu/>*), which is an open source program used for molecular docking that was designed and implemented by Dr. Oleg Trott at the Molecular Graphics Lab at The Scripps Research Institute \[[@b22-medscimonit-26-e920485]\], was used for batch docking of potential active ingredients in CS with the 5 proteins, and the results returned 9 conformations. The predominant conformation was analyzed and plotted with Free Maestro by Schrodinger (*<https://www.schrodinger.com/freemaestro>*).

Results
=======

Active ingredients of CS
------------------------

Seventy-six chemical ingredients of CS were identified in the TCMSP database. After setting the filtering criteria mentioned above, 11 active ingredients of CS were determined, which are shown in [Table 1](#t1-medscimonit-26-e920485){ref-type="table"}.

Potential targets of the active ingredients
-------------------------------------------

Through searching the TCMSP target module, 175 potential targets of CS active ingredients and their corresponding symbols were collected ([Supplementary Table 1](#s1-medscimonit-26-e920485){ref-type="supplementary-material"}).

Potential targets of OP
-----------------------

In this study, 3 internationally recognized databases of disease genes were searched, and 22 539 potential targets were retrieved after removing the duplicate targets. These targets were closely related to the occurrence and development of OP (Supplementary Table 2).

Ingredient and disease targets intersection
-------------------------------------------

After inputting the potential targets of the ingredients and the disease targets into the R platform, the intersection of the 2 types of targets was determined. The Venn diagram showed that 107 potential targets had relationships with active ingredients and OP ([Figure 1](#f1-medscimonit-26-e920485){ref-type="fig"}). The common gene names of the 107 potential targets are shown in [Supplementary Table 3](#s2-medscimonit-26-e920485){ref-type="supplementary-material"}.

M-I-T-D network
---------------

As shown in [Figure 2](#f2-medscimonit-26-e920485){ref-type="fig"}, a medicine-ingredients-targets-disease network was generated and indicated that these 4 components had close relationships with each other.

PPI network
-----------

In the "ingredients and disease intersection" part of the PPI network, OP targets and active ingredient potential targets showed 107 duplicate genes. These genes may become targets for the treatment of OP. To study the interaction of the targets *in vivo* and search for the hub genes, PPI network analysis of the potential target groups was carried out ([Figure 3](#f3-medscimonit-26-e920485){ref-type="fig"}). The linked tables with different colors represent the different meanings of the biological information. Moreover, the top 30 genes that had a close relationship with other genes were represented via a bar plot that clearly described these 30 gene targets in terms of their key positions in the PPI network. These genes were *MAPK8, EGFR, CCND1, IL-6, VEGFA, ESR1, AR, MYC, CASP3, PPARG, RELA, DECR1, NCOA1, ERBB2, FOS, ICAM1, NOS3, CYP1A1, PRKCA, CYP2B6, PGR, CASP8, CAV1, CYP3A4, GSTP1, NCOA2, RB1, VCAM1, AHR*, and *CD44* ([Figure 4](#f4-medscimonit-26-e920485){ref-type="fig"}).

GO and KEGG pathway enrichment analysis
---------------------------------------

To illustrate the mechanism underlying the effects of CS active ingredients on OP more comprehensively and concretely, we performed GO enrichment analysis of the 107 common targets in the ingredient-disease target network. As a result, the top 20 enriched GO terms were identified, which are shown in a bar plot (*P*-adjusted value \<0.01, [Figure 5](#f5-medscimonit-26-e920485){ref-type="fig"}). For example, in biological processes, the targets of CS were enriched in cofactor binding (GO: 0048037), proximal promoter sequence-specific DNA binding (GO: 0000987), DNA-binding transcription activator activity, RNA polymerase II proximal promoter sequence-specific binding (GO: 0001228), RNA polymerase II proximal promoter sequence-specific DNA binding (GO: 0000978), protein heterodimerization activity (GO: 0046982), chromatin binding (GO: 0003682), ubiquitin-like protein ligase binding (GO: 0044389), enzyme activator activity (GO: 0008047), and other processes. Meanwhile, a dot plot indicated the gene ratio of the number of target genes involved in one biological process to the number of all annotated genes. The higher the ratio, the higher the level of enrichment is. The size of the dot reflects the number of target genes in the analysis, and the different colors of the dots indicate the different *P*-adjusted value ranges ([Figure 6](#f6-medscimonit-26-e920485){ref-type="fig"}).

To elucidate the critical pathways among the 107 potential targets in terms of OP therapy, the top 20 pathways were filtered according to a *P*-adjusted value \< 0.01 ([Figure 7](#f7-medscimonit-26-e920485){ref-type="fig"}) and included pathways involved in fluid shear stress and atherosclerosis (hsa05418), Kaposi sarcoma-associated herpesvirus infection (hsa05167), proteoglycans in cancer (hsa05205), human cytomegalovirus infection (hsa05163), hepatitis B infection (hsa05161), Epstein-Barr virus infection (hsa05169), prostate cancer (hsa05215), AGE-RAGE signaling in diabetic complications (hsa04933), hepatocellular carcinoma (hsa05225), apoptosis (hsa04210), TNF signaling (hsa04668), measles infection (hsa05162), breast cancer, (hsa05224), colorectal cancer (hsa05210), thyroid hormone signaling (hsa04919), pancreatic cancer (hsa05212), p53 signaling (hsa04115), bladder cancer (hsa05219), prolactin signaling (hsa04917), and platinum drug resistance (hsa01524).

By applying an identical analytical method as that used for the GO analysis, a dot plot showing the relevant pathways was obtained that showed the same data as the GO dot plot ([Figure 8](#f8-medscimonit-26-e920485){ref-type="fig"}).

Active ingredient-main target molecular docking
-----------------------------------------------

Because 107 potential targets were obtained, the top 5 targets (*CCND1, EGFR, IL-6, MAPK8*, and *VEGFA*), which had higher scores, were selected for molecular docking with 11 active ingredients of CS. The ranking of the binding free energy of the 11 small molecule compounds was achieved, as shown in [Table 2](#t2-medscimonit-26-e920485){ref-type="table"}. This table indicates that the active ingredient sesamin bound to all 5 proteins better than the other ingredients.

We observed that all 11 ingredients entered the active pocket of the enzyme. For example, the analysis of sesamin indicated that sesamin bound to the active pocket of CCND1 and interacted with the H-bond of the amino group on LYS180 and weakly interacted via an aromatic hydrogen bond with CYS73 and GLU75 ([Figure 9](#f9-medscimonit-26-e920485){ref-type="fig"}). In [Figure 10](#f10-medscimonit-26-e920485){ref-type="fig"}, sesamin bound to the active pockets of EGFR and interacted with MET769, ALA698, and ARG817 to form hydrogen bonds and with GLN767, ASP813, and PHE699 to form weakly aromatic hydrogen bonds. Sesamin combined with the active pocket of IL-6 and interacted with and formed weakly aromatic hydrogen bonds with GLU42, THR43, and ASP 160, as shown in [Figure 11](#f11-medscimonit-26-e920485){ref-type="fig"}. Additionally, sesamin was linked to the active pocket of MAPK8 and interacted with MET111 to form hydrogen bonds. It also interacted with ASN156, ASP169, GLU109, and MET109 to form weakly aromatic hydrogen bonds ([Figure 12](#f12-medscimonit-26-e920485){ref-type="fig"}). Finally, sesamin bound to the active pocket of VEGFA and interacted with SER25 and TRP28 to form hydrogen bonds. The aromatic ring of RP28 interacted equally with the Pi-Pi bond and weakly with ASP47 to form aromatic hydrogen bonds ([Figure 13](#f13-medscimonit-26-e920485){ref-type="fig"}).

Discussion
==========

OP is characterized by low bone mass and a higher risk of fracture due to bone fragility. CS is a kind of bioactive ingredient extracted from plants. In recent years, it has been shown to play a vital role in bone metabolism through antioxidative and antiapoptotic effects \[[@b23-medscimonit-26-e920485]\]. Because of the variety of components in CS, the mechanism underlying its influence on OP is still unclear. Therefore, this study used a network pharmacology method to uncover the relevant relationships from multiple angles.

For example, certain studies on the relationship between sesamin, quercetin, and kaempferol and OP have been reported. Sesamin, also known as flax and flax oil, originated in the western regions of ancient China and belongs to the flax seed family \[[@b24-medscimonit-26-e920485]\]. It is mainly distributed in tropics worldwide. A previous study reported the protective effect of sesame oil against bone loss in an ovariectomized (OVX) rat model \[[@b25-medscimonit-26-e920485]\]. Orawan et al. indicated that after treatment with sesamin of human fetal osteoblasts and human adipose-derived stem cells, osteoblast differentiation could be activated through the p38 and ERK/MAPK pathways \[[@b26-medscimonit-26-e920485]\]. Moreover, Ma et al. reported that sesamin had the ability to promote the osteoblastic differentiation of BMSCs by regulating the Wnt/β-catenin pathway \[[@b27-medscimonit-26-e920485]\]. Tsuji et al. verified the inhibitory effect of quercetin on bone loss in an ovariectomized mouse model \[[@b28-medscimonit-26-e920485]\]. *In vivo* experiments also indicated that quercetin could improve BMSC activity and osteogenic differentiation ability \[[@b29-medscimonit-26-e920485]\]. A study by Adhikary et al. showed that supplementation with kaempferol could increase the speed of the healing of fractures caused by glucocorticoids and minimize bone loss in rats \[[@b30-medscimonit-26-e920485]\].

In this study, 107 common targets were analyzed via GO and KEGG enrichment analyses, and certain biological functions and signal pathways that had relationships with the ingredients and OP were determined. Based on the results, we speculated that the main biological functions involved DNA binding and protein or cofactor binding. Through these fundamental processes, CS may act on the relevant targets and thus affect the associated signaling pathways to exert drug effects. These pathways mainly play a role in certain cancers, TNF signaling pathways and stress signaling pathways. In a previous study, fluid shear stress (FSS) played a vital role in facilitating the proliferation and differentiation of osteoblasts \[[@b31-medscimonit-26-e920485]\] and reducing apoptosis \[[@b32-medscimonit-26-e920485]\]. As indicated by the bioinformatic findings of this study, the top 5 potential targets that were selected all had connections with OP.

MAPK8 performs the specific phosphorylation of the transcription factor c-Jun in the nucleus and is the kinase of c-Jun. Thus, MAPK8 is also called c-Jun amino-terminal kinase (JNK) \[[@b33-medscimonit-26-e920485]\]. JNK is one of most critical pathways related to osteoclastogenesis \[[@b34-medscimonit-26-e920485]\]. Some studies have confirmed this finding. Lee et al. used methylglyoxal to treat RAW264.7 macrophages and discovered that JNK was the most likely factor involved in activating osteoclasts \[[@b35-medscimonit-26-e920485]\]. Additionally, in another study, after treatment with a JNK inhibitor, researchers found that both the expression of mature osteoblast markers and mineralization of osteoblasts declined; however, upon the overexpression of JNK, osteoblast differentiation was enhanced \[[@b36-medscimonit-26-e920485]\]. Cyclin D1 (CCND1) plays an important role in regulating cell proliferation. A study indicated that chlorogenic acid exerted positive effects on BMSCs by activating cyclin D1 \[[@b37-medscimonit-26-e920485]\]. Other studies have also shown that enhanced cyclin D1 levels are associated with bone anabolism and anti-apoptosis \[[@b38-medscimonit-26-e920485]--[@b40-medscimonit-26-e920485]\]. Sato et al. focused on glucocorticoid-induced OP and demonstrated that when cyclin D1 was downregulated, bone formation was inhibited \[[@b41-medscimonit-26-e920485]\]. Interleukin (IL)-6 is a potent bone resorption factor that induces osteocyte differentiation and promotes osteoclast formation \[[@b42-medscimonit-26-e920485],[@b43-medscimonit-26-e920485]\]. A previous study showed that IL-6 was associated with increased activity of osteoclasts during postmenopausal OP \[[@b44-medscimonit-26-e920485]\]. In addition, animal experiments also revealed that knockout of the mouse IL-6 gene could prevent bone loss after ovariectomy (OVX) \[[@b45-medscimonit-26-e920485]\]. Therefore, IL-6 plays an important role in the pathogenesis of OP \[[@b46-medscimonit-26-e920485]\]. Vascular endothelial growth factor A (VEGFA) is a homologue of the VEGF family. It has been confirmed that there are functional VEGF receptors in primary osteoblasts, which allow VEGF to play a role in promoting osteoblast proliferation and bone remodeling \[[@b47-medscimonit-26-e920485]\]. A recent study also indicated that in mesenchymal stem cells (MSCs), VEGFA overexpression could enhance cell vitality and proliferation, and the expression levels of type I and type II collagen were evidently upregulated \[[@b48-medscimonit-26-e920485]\]. Meanwhile, a study by Min et al. showed that VEGFA also functions in osteoclast differentiation \[[@b49-medscimonit-26-e920485]\]. Epidermal growth factor receptor (EGFR) is the receptor of EGF, which affects osteoprogenitor maintenance and new bone formation \[[@b50-medscimonit-26-e920485]\]. At the same time, a study by Liu et al. revealed an interesting phenomenon in which the expression of p-EGFR on the endosteal surface of cortical bone was decreased in 15-month-old mice compared with that in 3-month-old mice \[[@b51-medscimonit-26-e920485]\]. This finding indicated that EGFR had a relationship with age in bone metabolism. Moreover, knockdown of EGFR in osteoblastic cells led to bone loss due to a decreased number of bone marrow mesenchymal progenitors \[[@b52-medscimonit-26-e920485]\]. In addition, it has also been reported that the mechanism of the regulation by EGFR of bone development involves the negative regulation of mTOR signaling during the process of osteoblastic differentiation \[[@b53-medscimonit-26-e920485]\]. As [Table 2](#t2-medscimonit-26-e920485){ref-type="table"} indicates, the lower the docking score, the higher the affinity of the docking molecule and the target was. Therefore, according to all the docking results, sesamin bound well to all 5 proteins. At the same time, based on the docking structure, we presume that the binding can be further improved by increasing the number of hydrogen bond interactions to enhance activity, which may allow sesamin to become a crucial agent for treating OP.

Conclusions
===========

By using a novel analysis approach, we tested the hypothesis that the Chinese herbal medicine, *Cuscutae semen* (CS), had a positive influence on the treatment and prevention of OP. Accordingly, this study further revealed the CS pharmacodynamic basis and mechanism of action involved in the treatment of OP at the systemic level. The most active ingredient in CS that produces its effect was predicted.

However, because this study depended on database and statistical code analysis to make predictions about the effectiveness of drugs, some limitations should be considered. Hence, our future research will focus on experimental studies to verify these hypotheses.

Supplementary Data
==================

###### 

Potential targets and corresponding symbols of *Cuscutae semen* (CS) active components.

  Mol Id      Mol name                Target                                                              Symbol
  ----------- ----------------------- ------------------------------------------------------------------- ---------
  MOL001558   Sesamin                 G1/S-specific cyclin-D1                                             CCND1
  MOL001558   Sesamin                 Fatty acid synthase                                                 FASN
  MOL001558   Sesamin                 Acetyl-CoA carboxylase 1                                            ACACA
  MOL001558   Sesamin                 Nitric oxide synthase, endothelial                                  NOS3
  MOL001558   Sesamin                 Endothelin-converting enzyme 1                                      ECE1
  MOL001558   Sesamin                 Cytochrome P450 2B6                                                 CYP2B6
  MOL001558   Sesamin                 Sterol regulatory element-binding protein 1                         SREBF1
  MOL001558   Sesamin                 NADPH oxidase 1                                                     NOX1
  MOL001558   Sesamin                 Peroxisomal acyl-coenzyme A oxidase 1                               ACOX1
  MOL001558   Sesamin                 Peroxisomal bifunctional enzyme                                     EHHADH
  MOL001558   Sesamin                 Trifunctional enzyme subunit beta, mitochondrial                    HADHB
  MOL001558   Sesamin                 2,4-dienoyl-CoA reductase, mitochondrial                            DECR1
  MOL000184   NSC63551                Progesterone receptor                                               PGR
  MOL000354   Isorhamnetin            Prostaglandin G/H synthase 1                                        PTGS1
  MOL000354   Isorhamnetin            Estrogen receptor                                                   ESR1
  MOL000354   Isorhamnetin            Androgen receptor                                                   AR
  MOL000354   Isorhamnetin            Peroxisome proliferator activated receptor gamma                    PPARG
  MOL000354   Isorhamnetin            Estrogen receptor beta                                              ESR2
  MOL000354   Isorhamnetin            Glycogen synthase kinase-3 beta                                     GSK3B
  MOL000354   Isorhamnetin            Trypsin-1                                                           PRSS1
  MOL000354   Isorhamnetin            Nuclear receptor coactivator 2                                      NCOA2
  MOL000354   Isorhamnetin            Serine/threonine-protein kinase Chk1                                CHEK1
  MOL000354   Isorhamnetin            Aldose reductase                                                    AKR1B1
  MOL000354   Isorhamnetin            Nuclear receptor coactivator 1                                      NCOA1
  MOL000354   Isorhamnetin            Coagulation factor VII                                              F7
  MOL000354   Isorhamnetin            Acetylcholinesterase                                                ACHE
  MOL000354   Isorhamnetin            Gamma-aminobutyric acid receptor subunit alpha-1                    GABRA1
  MOL000354   Isorhamnetin            Glutamate receptor 2                                                GRIA2
  MOL000354   Isorhamnetin            Transcription factor p65                                            RELA
  MOL000354   Isorhamnetin            Oxidized low-density lipoprotein receptor 1                         OLR1
  MOL000358   beta-Sitosterol         Progesterone receptor                                               PGR
  MOL000358   beta-Sitosterol         Nuclear receptor coactivator 2                                      NCOA2
  MOL000358   beta-Sitosterol         Prostaglandin G/H synthase 1                                        PTGS1
  MOL000358   beta-Sitosterol         Muscarinic acetylcholine receptor M3                                CHRM3
  MOL000358   beta-Sitosterol         Muscarinic acetylcholine receptor M1                                CHRM1
  MOL000358   beta-Sitosterol         Muscarinic acetylcholine receptor M4                                CHRM4
  MOL000358   beta-Sitosterol         Alpha-1A adrenergic receptor                                        ADRA1A
  MOL000358   beta-Sitosterol         Muscarinic acetylcholine receptor M2                                CHRM2
  MOL000358   beta-Sitosterol         Neuronal acetylcholine receptor subunit alpha-2                     CHRNA2
  MOL000358   beta-Sitosterol         Gamma-aminobutyric acid receptor subunit alpha-1                    GABRA1
  MOL000358   beta-Sitosterol         Apoptosis regulator Bcl-2                                           BCL2
  MOL000358   beta-Sitosterol         Caspase-9                                                           CASP9
  MOL000358   beta-Sitosterol         Caspase-3                                                           CASP3
  MOL000358   beta-Sitosterol         Caspase-8                                                           CASP8
  MOL000358   beta-Sitosterol         Protein kinase C alpha type                                         PRKCA
  MOL000358   beta-Sitosterol         Serum paraoxonase/arylesterase 1                                    PON1
  MOL000422   Kaempferol              Prostaglandin G/H synthase 1                                        PTGS1
  MOL000422   Kaempferol              Androgen receptor                                                   AR
  MOL000422   Kaempferol              Peroxisome proliferator activated receptor gamma                    PPARG
  MOL000422   Kaempferol              Nuclear receptor coactivator 2                                      NCOA2
  MOL000422   Kaempferol              Trypsin-1                                                           PRSS1
  MOL000422   Kaempferol              Progesterone receptor                                               PGR
  MOL000422   Kaempferol              Muscarinic acetylcholine receptor M1                                CHRM1
  MOL000422   Kaempferol              Acetylcholinesterase                                                ACHE
  MOL000422   Kaempferol              Muscarinic acetylcholine receptor M2                                CHRM2
  MOL000422   Kaempferol              Gamma-aminobutyric acid receptor subunit alpha-1                    GABRA1
  MOL000422   Kaempferol              Coagulation factor VII                                              F7
  MOL000422   Kaempferol              Transcription factor p65                                            RELA
  MOL000422   Kaempferol              Inhibitor of nuclear factor kappa-B kinase subunit beta             IKBKB
  MOL000422   Kaempferol              Apoptosis regulator Bcl-2                                           BCL2
  MOL000422   Kaempferol              Activator of 90 kDa heat shock protein ATPase homolog 1             AHSA1
  MOL000422   Kaempferol              Caspase-3                                                           CASP3
  MOL000422   Kaempferol              Mitogen-activated protein kinase 8                                  MAPK8
  MOL000422   Kaempferol              Peroxisome proliferator-activated receptor gamma                    PPARG
  MOL000422   Kaempferol              Cytochrome P450 3A4                                                 CYP3A4
  MOL000422   Kaempferol              Cytochrome P450 1A1                                                 CYP1A1
  MOL000422   Kaempferol              Intercellular adhesion molecule 1                                   ICAM1
  MOL000422   Kaempferol              E-selectin                                                          SELE
  MOL000422   Kaempferol              Vascular cell adhesion protein 1                                    VCAM1
  MOL000422   Kaempferol              Cytochrome P450 1B1                                                 CYP1B1
  MOL000422   Kaempferol              Arachidonate 5-lipoxygenase                                         ALOX5
  MOL000422   Kaempferol              Glutathione S-transferase P                                         GSTP1
  MOL000422   Kaempferol              Aryl hydrocarbon receptor                                           AHR
  MOL000422   Kaempferol              26S proteasome non-ATPase regulatory subunit 3                      PSMD3
  MOL000422   Kaempferol              Solute carrier family 2, facilitated glucose transporter member 4   SLC2A4
  MOL000422   Kaempferol              Nuclear receptor subfamily 1 group I member 3                       NR1I3
  MOL000422   Kaempferol              Type I iodothyronine deiodinase                                     DIO1
  MOL000422   Kaempferol              Glutathione S-transferase Mu 1                                      GSTM1
  MOL000422   Kaempferol              Glutathione S-transferase Mu 2                                      GSTM2
  MOL000422   Kaempferol              Aldo-keto reductase family 1 member C3                              AKR1C3
  MOL005043   Campest-5-en-3beta-ol   Progesterone receptor                                               PGR
  MOL005440   Isofucosterol           Progesterone receptor                                               PGR
  MOL005440   Isofucosterol           Mineralocorticoid receptor                                          NR3C2
  MOL005440   Isofucosterol           4-aminobutyrate aminotransferase, mitochondrial                     ABAT
  MOL005440   Isofucosterol           Gamma-aminobutyric acid receptor subunit alpha-1                    GABRA1
  MOL005440   Isofucosterol           Alcohol dehydrogenase 1B                                            ADH1B
  MOL005440   Isofucosterol           Nuclear receptor coactivator 2                                      NCOA2
  MOL005944   Matrine                 Transcription factor p65                                            RELA
  MOL005944   Matrine                 Interleukin-6                                                       IL6
  MOL005944   matrine                 Caspase-3                                                           CASP3
  MOL005944   Matrine                 Myc proto-oncogene protein                                          MYC
  MOL005944   Matrine                 Intercellular adhesion molecule 1                                   ICAM1
  MOL005944   Matrine                 Heparanase                                                          HPSE
  MOL005944   Matrine                 Immediate early response 3-interacting protein 1                    IER3IP1
  MOL005944   Matrine                 CD44 antigen                                                        CD44
  MOL000953   CLR                     Progesterone receptor                                               PGR
  MOL000953   CLR                     Mineralocorticoid receptor                                          NR3C2
  MOL000953   CLR                     Nuclear receptor coactivator 2                                      NCOA2
  MOL000098   Quercetin               Prostaglandin G/H synthase 1                                        PTGS1
  MOL000098   Quercetin               Androgen receptor                                                   AR
  MOL000098   Quercetin               Peroxisome proliferator activated receptor gamma                    PPARG
  MOL000098   Quercetin               Nuclear receptor coactivator 2                                      NCOA2
  MOL000098   Quercetin               Aldose reductase                                                    AKR1B1
  MOL000098   Quercetin               Trypsin-1                                                           PRSS1
  MOL000098   Quercetin               Coagulation factor VII                                              F7
  MOL000098   Quercetin               Acetylcholinesterase                                                ACHE
  MOL000098   Quercetin               Gamma-aminobutyric acid receptor subunit alpha-1                    GABRA1
  MOL000098   Quercetin               Transcription factor p65                                            RELA
  MOL000098   Quercetin               Epidermal growth factor receptor                                    EGFR
  MOL000098   Quercetin               Vascular endothelial growth factor A                                VEGFA
  MOL000098   Quercetin               G1/S-specific cyclin-D1                                             CCND1
  MOL000098   Quercetin               Apoptosis regulator Bcl-2                                           BCL2
  MOL000098   Quercetin               Proto-oncogene c-Fos                                                FOS
  MOL000098   Quercetin               Eukaryotic translation initiation factor 6                          EIF6
  MOL000098   Quercetin               Caspase-9                                                           CASP9
  MOL000098   Quercetin               Urokinase-type plasminogen activator                                PLAU
  MOL000098   Quercetin               Retinoblastoma-associated protein                                   RB1
  MOL000098   Quercetin               Interleukin-6                                                       IL6
  MOL000098   Quercetin               Activator of 90 kDa heat shock protein ATPase homolog 1             AHSA1
  MOL000098   Quercetin               Caspase-3                                                           CASP3
  MOL000098   Quercetin               Cellular tumor antigen p53                                          TP63
  MOL000098   Quercetin               ETS domain-containing protein Elk-1                                 ELK1
  MOL000098   Quercetin               NF-kappa-B inhibitor alpha                                          NFKBIA
  MOL000098   Quercetin               NADPH\--cytochrome P450 reductase                                   POR
  MOL000098   Quercetin               Caspase-8                                                           CASP8
  MOL000098   Quercetin               RAF proto-oncogene serine/threonine-protein kinase                  RAF1
  MOL000098   Quercetin               Protein kinase C alpha type                                         PRKCA
  MOL000098   Quercetin               Hypoxia-inducible factor 1-alpha                                    HIF1A
  MOL000098   Quercetin               Protein CBFA2T1                                                     RUNX1T1
  MOL000098   Quercetin               Receptor tyrosine-protein kinase erbB-2                             ERBB2
  MOL000098   Quercetin               Peroxisome proliferator-activated receptor gamma                    PPARG
  MOL000098   Quercetin               Acetyl-CoA carboxylase 1                                            ACACA
  MOL000098   Quercetin               Cytochrome P450 3A4                                                 CYP3A4
  MOL000098   Quercetin               Caveolin-1                                                          CAV1
  MOL000098   Quercetin               Myc proto-oncogene protein                                          MYC
  MOL000098   Quercetin               Cytochrome P450 1A1                                                 CYP1A1
  MOL000098   Quercetin               Intercellular adhesion molecule 1                                   ICAM1
  MOL000098   Quercetin               E-selectin                                                          SELE
  MOL000098   Quercetin               Vascular cell adhesion protein 1                                    VCAM1
  MOL000098   Quercetin               Prostaglandin E2 receptor EP3 subtype                               PTGER3
  MOL000098   Quercetin               Baculoviral IAP repeat-containing protein 5                         BIRC5
  MOL000098   Quercetin               Dual oxidase 2                                                      DUOX2
  MOL000098   Quercetin               Nitric oxide synthase, endothelial                                  NOS3
  MOL000098   Quercetin               Heat shock protein beta-1                                           HSPB1
  MOL000098   Quercetin               Maltase-glucoamylase, intestinal                                    MGAM
  MOL000098   Quercetin               Cytochrome P450 1B1                                                 CYP1B1
  MOL000098   Quercetin               G2/mitotic-specific cyclin-B1                                       CCNB1
  MOL000098   Quercetin               Arachidonate 5-lipoxygenase                                         ALOX5
  MOL000098   Quercetin               Glutathione S-transferase P                                         GSTP1
  MOL000098   Quercetin               Nuclear factor erythroid 2-related factor 2                         NFE2L2
  MOL000098   Quercetin               NAD(P)H dehydrogenase \[quinone\] 1                                 NQO1
  MOL000098   Quercetin               Poly \[ADP-ribose\] polymerase 1                                    PARP1
  MOL000098   Quercetin               Aryl hydrocarbon receptor                                           AHR
  MOL000098   Quercetin               26S proteasome non-ATPase regulatory subunit 3                      PSMD3
  MOL000098   Quercetin               Solute carrier family 2, facilitated glucose transporter member 4   SLC2A4
  MOL000098   Quercetin               Collagen alpha-1(III) chain                                         COL3A1
  MOL000098   Quercetin               DDB1- and CUL4-associated factor 5                                  DCAF5
  MOL000098   Quercetin               Nuclear receptor subfamily 1 group I member 3                       NR1I3
  MOL000098   Quercetin               Serine/threonine-protein kinase Chk2                                CHEK2
  MOL000098   Quercetin               Heat shock factor protein 1                                         HSF1
  MOL000098   Quercetin               C-reactive protein                                                  CRP
  MOL000098   Quercetin               Runt-related transcription factor 2                                 RUNX2
  MOL000098   Quercetin               Ras association domain-containing protein 1                         RASSF1
  MOL000098   Quercetin               Cathepsin D                                                         CTSD
  MOL000098   Quercetin               Insulin-like growth factor-binding protein 3                        IGFBP3
  MOL000098   Quercetin               Insulin-like growth factor II                                       IGF2
  MOL000098   Quercetin               Interferon regulatory factor 1                                      IRF1
  MOL000098   Quercetin               Receptor tyrosine-protein kinase erbB-3                             ERBB3
  MOL000098   Quercetin               Serum paraoxonase/arylesterase 1                                    PON1
  MOL000098   Quercetin               Type I iodothyronine deiodinase                                     DIO1
  MOL000098   Quercetin               Puromycin-sensitive aminopeptidase                                  NPEPPS
  MOL000098   Quercetin               Hexokinase-2                                                        HK2
  MOL000098   Quercetin               Ras GTPase-activating protein 1                                     RASA1
  MOL000098   Quercetin               Glutathione S-transferase Mu 1                                      GSTM1
  MOL000098   Quercetin               Glutathione S-transferase Mu 2                                      GSTM2

###### 

107 common genes of ingredients and osteoporosis.

  --------- ---------
  CCND1     NCOA2
  FASN      CHEK1
  ACACA     AKR1B1
  NOS3      NCOA1
  ECE1      F7
  CYP2B6    ACHE
  SREBF1    GABRA1
  NOX1      GRIA2
  ACOX1     RELA
  EHHADH    OLR1
  HADHB     CHRM3
  DECR1     CHRM1
  PGR       CHRM4
  PTGS1     ADRA1A
  ESR1      CHRM2
  AR        CHRNA2
  PPARG     BCL2
  ESR2      CASP9
  GSK3B     CASP3
  PRSS1     CASP8
  PRKCA     AKR1C3
  PON1      NR3C2
  IKBKB     ABAT
  AHSA1     ADH1B
  MAPK8     IL6
  CYP3A4    MYC
  CYP1A1    HPSE
  ICAM1     IER3IP1
  SELE      CD44
  VCAM1     EGFR
  CYP1B1    VEGFA
  ALOX5     FOS
  GSTP1     EIF6
  AHR       PLAU
  PSMD3     RB1
  SLC2A4    TP63
  NR1I3     ELK1
  DIO1      NFKBIA
  GSTM1     POR
  GSTM2     RAF1
  HIF1A     HSPB1
  RUNX1T1   CCNB1
  ERBB2     NFE2L2
  CAV1      NQO1
  PTGER3    PARP1
  BIRC5     COL3A1
  DUOX2     DCAF5
  CHEK2     IGF2
  HSF1      IRF1
  CRP       ERBB3
  RUNX2     NPEPPS
  RASSF1    HK2
  CTSD      RASA1
  IGFBP3    
  --------- ---------
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**Supplementary Table 2.** Potential targets of osteoporosis.

Supplementary Table 2 available from the corresponding author on request.

![Venn diagram of 107 potential common targets.](medscimonit-26-e920485-g001){#f1-medscimonit-26-e920485}

![A medicine-ingredients-targets-disease network of 4 parts. CS: *Cuscutae Semen*; yellow: active ingredients of CS; red: 107 potential common targets.](medscimonit-26-e920485-g002){#f2-medscimonit-26-e920485}

![Protein--protein interaction (PPI) network analysis of 107 potential target: cyan line: from curated databases; purple line: experimentally determined; green line: gene neighborhood; red line: gene fusions; blue line: gene co-occurrence; yellow line: text mining; black line: co-expression; baby blue line: protein homology.](medscimonit-26-e920485-g003){#f3-medscimonit-26-e920485}

![Top 30 targets from protein--protein interaction (PPI) network.](medscimonit-26-e920485-g004){#f4-medscimonit-26-e920485}

![Top 20 enriched Gene Ontology (GO) terms selected from 107 common targets. (*P-*adjust value \<0.01).](medscimonit-26-e920485-g005){#f5-medscimonit-26-e920485}

![A dot plot to describe *P-*adjust value range of top 20 targets.](medscimonit-26-e920485-g006){#f6-medscimonit-26-e920485}

![Top 20 pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG). (*P*-adjust value \<0.01).](medscimonit-26-e920485-g007){#f7-medscimonit-26-e920485}

![A dot plot to describe *P*-adjust value range of top 20 pathways.](medscimonit-26-e920485-g008){#f8-medscimonit-26-e920485}

![Sesamin bound to the active pocket of cyclin D1 (CCND1).](medscimonit-26-e920485-g009){#f9-medscimonit-26-e920485}

![Sesamin bound to the active pocket of epidermal growth factor receptor (EGFR).](medscimonit-26-e920485-g010){#f10-medscimonit-26-e920485}

![Sesamin bound to the active pocket of interleukin-6 (IL6).](medscimonit-26-e920485-g011){#f11-medscimonit-26-e920485}

![Sesamin bound to the active pocket of mitogen-activated protein kinase 8 (MAPK8).](medscimonit-26-e920485-g012){#f12-medscimonit-26-e920485}

![Sesamin bound to the active pocket of vascular endothelial growth factor A (VEGFA).](medscimonit-26-e920485-g013){#f13-medscimonit-26-e920485}

###### 

Active components of *Cuscutae semen* (CS).

  Mol ID      Mol name                OB (%)   DL
  ----------- ----------------------- -------- ------
  MOL001558   Sesamin                 56.55    0.83
  MOL000184   NSC63551                39.25    0.76
  MOL000354   Isorhamnetin            49.6     0.31
  MOL000358   beta-Sitosterol         36.91    0.75
  MOL000422   kaempferol              41.88    0.24
  MOL005043   Campest-5-en-3beta-ol   37.58    0.71
  MOL005440   Isofucosterol           43.78    0.76
  MOL005944   Matrine                 63.77    0.25
  MOL006649   Sophranol               55.42    0.28
  MOL000953   CLR                     37.87    0.68
  MOL000098   Quercetin               46.43    0.28

###### 

Binding free energy of 11 small molecules.

  Affinity (kcal/mol)     CCND1   EGFR   IL6    MAPK8   VEGFA
  ----------------------- ------- ------ ------ ------- -------
  Sesamin                 −7.1    −9.3   −7.3   −8.7    −6.9
  Isorhamnetin            −6.6    −8.4   −6.2   −7.6    −6.0
  CLR                     −6.2    −8.2   −6.9   −8.0    −5.6
  Sophranol               −6.6    −8     −5.7   −7.9    −5.4
  Matrine                 −6.5    −7.8   −6.1   −7.5    −5.4
  Kaempferol              −6.7    −8.2   −6.2   −7.6    −6.2
  Isofucosterol           −6.3    −7.4   −6.6   −8.8    −6.0
  Campest-5-en-3beta-ol   −6.5    −7.8   −6.2   −8.3    −5.6
  NSC63551                −6.6    −8.0   −6.4   −7.9    −6.3
  Quercetin               −7.1    −8.0   −6.0   −7.0    −6.9
  beta-Sitosterol         −6.2    −7.1   −6.2   −8.1    −5.8
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